AHCC supplement as immune booster in liver cancer immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests whether AHCC, a natural supplement, can help boost your immune system while you receive standard immunotherapy for liver cancer. Researchers want to see if it makes the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer and are scheduled to receive immunotherapy.
- You have at least one measurable liver tumor that hasn't been treated with surgery or radiation.
- You are age 20 or older.
- You are fully active or only slightly limited in daily activities (ECOG 0 or 1).
- Your blood counts and liver/kidney function are within safe ranges (white blood cells ≥ 2000, platelets ≥ 60,000, certain liver enzymes and kidney function tests acceptable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.